Novartis' (NVS +1%) AIN457 treatment may significantly improve moderate-to-severe plaque...

|About: Novartis AG (NVS)|By:, SA News Editor

Novartis' (NVS +1%) AIN457 treatment may significantly improve moderate-to-severe plaque psoriasis on the hands, feet and nails, Phase II data shows. Around 125M worldwide suffer from plaque psoriasis, a hard-to-treat chronic disease characterized by thick and extensive skin lesions that cause itching, scaling and pain. (PR)